The Cardiovascular and Autonomic Effects of Repeated Administration of Delta-9-tetrahydrocannabinol to Rhesus Monkeys
Overview
Affiliations
The cardiovascular effects of repeated dosing with delta-9-tetrahydrocannabinol (THC) were examined in chronically catheterized, conscious rhesus monkeys. THC (0.5 mg/kg) was administered i.v. every 6 hr for 3 weeks. Following the first THC bolus, a tachycardia (peak change, 34 beats/min) and hypotension (peak change, -21 mm Hg systolic blood pressure) sometimes preceded by a transient blood pressure increase were observed. Tolerance developed to the tachycardia and systolic blood pressure increase but not to the blood pressure decrease. Hourly measurement of systolic blood pressure and heart rate during the intervals between injections revealed heart rate decreases to which tolerance developed and blood pressure decreases which were sustained throughout the course of TCH dosing. Urinary catecholamine excretion increased during the 1st week of dosing and subsequently returned toward base-line levels. Control of basal heart rate and reflex heart rate changes was examined using autonomic agonists and antagonists. Heart rate decreases after beta adrenergic blockage (sotalol HCl) were attenuated, whereas heart rate increases after cholinergic blockade (atropine methylnitrate increases after cholinergic blockade (atropine methylnitrate) were augmented. Baroreceptor gain, measured as the ratio of heart rate change to systolic blood pressure change in response to phenylephrine, increased. The response of basal heart rate to antagonists and the augmented reflex bradycardia suggest that THC alters autonomic control of the cardiovascular system resulting in parasympathetic dominance. Divergent patterns of development of tolerance to heart rate and blood pressure effects suggest that THC affects heart rate and blood pressure through different mechanisms.
Applications of Cannabinoids in Neuropathic Pain: An Updated Review.
Arthur P, Kalvala A, Surapaneni S, Singh M Crit Rev Ther Drug Carrier Syst. 2023; 41(1):1-33.
PMID: 37824417 PMC: 11228808. DOI: 10.1615/CritRevTherDrugCarrierSyst.2022038592.
Weresa J, Pedzinska-Betiuk A, Minczuk K, Malinowska B, Schlicker E Cells. 2022; 11(7).
PMID: 35406706 PMC: 8997492. DOI: 10.3390/cells11071142.
CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design.
Das A, Weigle A, Arnold W, Kim J, Carnevale L, Huff H Pharmacol Ther. 2020; 215:107601.
PMID: 32534953 PMC: 7773148. DOI: 10.1016/j.pharmthera.2020.107601.
Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.
Wilkerson J, Schulze D, McMahon L PLoS One. 2019; 14(3):e0209947.
PMID: 30861005 PMC: 6413903. DOI: 10.1371/journal.pone.0209947.
Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.
Arnold W, Weigle A, Das A J Inorg Biochem. 2018; 184:88-99.
PMID: 29689453 PMC: 5964033. DOI: 10.1016/j.jinorgbio.2018.03.016.